Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More
Xconomy
FEBRUARY 14, 2020
Post-marketing studies aim to identify side effects not observed in the first three phases of testing. This week, results of such a study led to the market withdrawal of weight-loss pill lorcaserin (Belviq). When the FDA approved the drug in 2012, the agency was concerned about heart risks.
Let's personalize your content